BioCentury | Feb 18, 2020
Product Development

Riptide peptide turns TAMs proinflammatory

...with poor overall survival. "We believe that this CD206 motif represents a novel immune checkpoint," Riptide Bioscience Inc....
...disclose a development timeline. Targets K-Ras (KRAS) MBR (CD206) - Mannose binding receptor Sandi Wong, Assistant Editor RP182 Riptide Bioscience Inc. Mannose...
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...in 2017 to get a cancer candidate and an antimicrobial through Phase I. COMPANY PROFILE Riptide Bioscience Inc....
...Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd., Aberdeen, U.K. Pergamum AB, Solna, Sweden Riptide Bioscience Inc....
...Bay, Israel Tuskegee University, Tuskegee, Ala. U.S. Department of Defense, Washington, D.C. Erin McCallister, Senior Editor RP182 Genaera Corp. Riptide Bioscience Inc. Infectious...
Items per page:
1 - 2 of 2
BioCentury | Feb 18, 2020
Product Development

Riptide peptide turns TAMs proinflammatory

...with poor overall survival. "We believe that this CD206 motif represents a novel immune checkpoint," Riptide Bioscience Inc....
...disclose a development timeline. Targets K-Ras (KRAS) MBR (CD206) - Mannose binding receptor Sandi Wong, Assistant Editor RP182 Riptide Bioscience Inc. Mannose...
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...in 2017 to get a cancer candidate and an antimicrobial through Phase I. COMPANY PROFILE Riptide Bioscience Inc....
...Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd., Aberdeen, U.K. Pergamum AB, Solna, Sweden Riptide Bioscience Inc....
...Bay, Israel Tuskegee University, Tuskegee, Ala. U.S. Department of Defense, Washington, D.C. Erin McCallister, Senior Editor RP182 Genaera Corp. Riptide Bioscience Inc. Infectious...
Items per page:
1 - 2 of 2